240
Participants
Start Date
October 28, 2020
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
XR-B
Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
XR-NTX
Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
Friends Research Institute, Baltimore
Lead Sponsor
Friends Research Institute, Inc.
OTHER